An interventional study of Feedback group and Non Feedback group in Acne Vulgaris, sponsored by University of California, Davis. Completed at 1 site in United States. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2018-07-02.
Sponsored by University of California, Davis · Not applicable, Interventional, and Treatment
To see if teledermatology can be used to reduce antibiotic burden in patients on doxycycline or minocycline for acne vulgaris
The investigators are going to ascertain if antibiotic burden can be reduced with tele dermatology use.
There are two arms of the study:
All subjects will be randomised to either group, all subjects will take photos of their face and answer questions at baseline, visit 2 (1 month), visit 3 (2 months), visit 4 (3 months).
The investigators will then use measurements of acne grading (patient grading, investigator global assessment, lesion counting, global acne grading) to reduce/taper antibiotics in the feedback group.
730 studies on the registry are indexed under Acne Vulgaris; 86 are open to participants now.
This study's enrollment of 4 is below the median of 69 across 628 interventional studies indexed under Acne Vulgaris.
Browse Acne Vulgaris studies →University of California, Davis is the lead sponsor of 798 studies on the registry; 146 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 43 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
No feedback given to this group regarding their antibiotic use Subjects take images and answer questions during the study like the feedback group, but in this group no feedback re dosing is given.
Other: Non Feedback group
Feedback given to this group regarding their antibiotic use after baseline. If the subject is in the feedback group, after this visit, a dermatologist will review all images and the survey results and give the patient information about whether they should: 1. Continue current dose 2. Reduce dose if there is at least a one point improvement in both the investigator acne global assessment AND the patient acne global assessment scores: A dose reduction will be such that the dose is halved from the previous dose. For example if the subject is on minocycline or doxycycline 100 mg twice daily, they will be reduced to minocycline or doxycycline 100 mg daily. 3. Increase dose if had been previously reduced, dose will not be increased beyond the initial starting dose.
Other: Feedback group
Monitoring ability to use teledermatology to modify antibiotic burden
To use as control to see if antibiotic burden has been reduced in the active feedback group
Reduced antibiotic use
The difference in antibiotic exposure in the physician feedback group compared to those not receiving feedback
Time frame: Assessed at 4, 8, 12 weeks
Change in acne grading (change in patient grading)
Change in Patient Grading
Time frame: Assessed at 4, 8, 12 weeks
Change in acne grading (investigator global assessment)
Change in Investigator Global Assessment
Time frame: Assessed at 4, 8, 12 weeks
Change in acne grading (lesion counting)
Change in Lesion Counting
Time frame: Assessed at 4, 8, 12 weeks
Change in acne grading using the global acne grading
Change in Global Acne Grading
Time frame: Assessed at 4, 8, 12 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Davis